For 1QFY2018 Aurobindo Pharma (APL) posted numbers lower than expectations on sales, OPM and net profit fronts. On sales front, the company posted sales of `3621cr (v/s. `3,900cr expected) v/s. `3,664cr in 1QFY2017, posting a yoy de-growth of 1.2%. On the operating front, the EBITDA margin came in at 21.1% (v/s. 22.9% expected) v/s. 22.6% in 1QFY2017. Consequently, the Adj. PAT came in at `519cr (v/s. `641cr expected) v/s. `585cr in 1QFY2017, a yoy de-growth of 11.4%. We maintain our Buy rating on the stock.

Download Full Report View Full Report in Browser